Dear Editor, Multiple myeloma (MM) is a disease characterized by the clonal expansion of malignant plasma cells in the marrow, leading to anemia, hypercalcemia, bone lesion, and renal dysfunction [1]. Immunoglobulin D...Dear Editor, Multiple myeloma (MM) is a disease characterized by the clonal expansion of malignant plasma cells in the marrow, leading to anemia, hypercalcemia, bone lesion, and renal dysfunction [1]. Immunoglobulin D (IgD) myeloma is a rare subtype of MM, accounting for approximately 1% to 2% of all MM patients [2]. It occurs at a young age, often accom-panied with a high disease burden and short median sur-vival (18-21 months) [3, 4]. Several studies have suggested that in patients with IgD subtype, the outcomes of those who have had undergone autologous stem cell transplanta-tion (ASCT) were superior than those treated with chemo-therapy alone [5, 6]. However, these have been debatable as other reports have displayed opposite results [7, 8].展开更多
文摘Dear Editor, Multiple myeloma (MM) is a disease characterized by the clonal expansion of malignant plasma cells in the marrow, leading to anemia, hypercalcemia, bone lesion, and renal dysfunction [1]. Immunoglobulin D (IgD) myeloma is a rare subtype of MM, accounting for approximately 1% to 2% of all MM patients [2]. It occurs at a young age, often accom-panied with a high disease burden and short median sur-vival (18-21 months) [3, 4]. Several studies have suggested that in patients with IgD subtype, the outcomes of those who have had undergone autologous stem cell transplanta-tion (ASCT) were superior than those treated with chemo-therapy alone [5, 6]. However, these have been debatable as other reports have displayed opposite results [7, 8].
